President and Chief Executive Officer
Andy Sheldon has been President and Chief Executive Officer of Medicago since August 2003. He has thirty years of experience in the pharmaceutical industry, and was named CEO of the Year by the Vaccine Industry Excellence awards at the World Vaccine Congress in April 2012.
Before joining the Company, Mr Sheldon was Vice-President, Sales and Marketing of Shire Biologics. He was responsible for international expansion with European, American and Asian private partnership agreements. He was also responsible for distribution, customer service, conflicts of interest and engineering at the Shire facility. He successfully negotiated the annual and pandemic influenza vaccine contract with the federal and provincial governments.
From 1998 to 2000, he was Senior Manager of Commercial Operations where he successfully managed the approval of a bladder cancer therapeutic vaccine by the FDA. In 1997 and 1998, he was Marketing Manager for Merial Canada Inc. From 1992 to 1997, he was Director of Canadian Operations with Rhône Mérieux. From 1988 to 1992, he was National Sales Manager for SmithKline Beecham. Mr. Sheldon has a Bachelors degree in agricultural sciences from Université Laval, Québec City and a Bachelors of science degree with honors in biological sciences from the University of East Anglia, Norwich, England.